Alpinetin Nanoparticles Protect Retinal Neurons in Glaucoma by Resetting Microglial Fat Metabolism
Alpinetin-loaded nanoparticles bind LRP1 in retinal microglia, clear lipid buildup, calm inflammation and preserve retinal ganglion cells in an acute glaucoma model.
Résumé
Glaucoma damages retinal ganglion cells even when eye pressure is controlled, and immune cells called microglia are implicated. Researchers found that in an acute ocular hypertension model, retinal microglia accumulated lipid droplets, lost the receptor LRP1 and shifted toward a pro-inflammatory state. Serum LRP1 was also lower in glaucoma patients than in cataract controls. To reverse this, the team packaged the plant flavonoid alpinetin into PLGA nanoparticles (AlpNPs). These were taken up by microglia, reduced lipid accumulation, favored an anti-inflammatory phenotype and limited microglial proliferation and migration. The effect depended on LRP1, which AlpNPs bound and which then engaged PPARγ and the LXRα-ABCA1 cholesterol-efflux pathway. Injected into the eye, AlpNPs reduced retinal inflammation and preserved ganglion cells. The work is preclinical but points to LRP1-targeted nanotherapy as a possible neuroprotective strategy.
Résumé détaillé
Glaucoma is a leading cause of irreversible blindness, driven by progressive loss of retinal ganglion cells (RGCs). Many patients keep losing vision even when intraocular pressure is well controlled, so pressure-independent mechanisms such as neuroinflammation matter. Microglia, the retina's resident immune cells, can shift between a damaging pro-inflammatory (M1-like) state and a reparative (M2-like) state. Lipid handling is increasingly recognized as a driver of that switch in Alzheimer's and Parkinson's disease, but it had not been well studied in glaucoma.
The researchers used a mouse-style acute ocular hypertension (AOH) model, in which pressure peaked at about 98 mmHg during the ischemic phase and then returned to normal. The retinas showed thinning, ganglion cell layer loss and fewer RGCs. They also showed increased lipid droplets (by flow cytometry and flat-mount imaging) and lipid droplet protein Plin2 in Iba1-positive microglia. Analysis of three public glaucoma transcriptomic datasets (GSE130610, GSE192509, GSE43671), intersected with lipid-droplet-related genes, highlighted LRP1 and VAPB. Retinal Lrp1 protein fell in AOH, and ELISA showed lower serum LRP1 in patients with primary open-angle and primary angle-closure glaucoma than in age-related cataract controls.
To target this, the team encapsulated alpinetin, a poorly soluble flavonoid with known anti-inflammatory activity, in PLGA nanoparticles (AlpNPs) for sustained release. According to the abstract, microglia took up AlpNPs efficiently. The particles reduced intracellular lipid accumulation, promoted M2 polarization and suppressed microglial proliferation and migration. Mechanistically, AlpNPs bound directly to LRP1 and strengthened its interaction with PPARγ. This activated the downstream LXRα-ABCA1 pathway, which drives cholesterol efflux and anti-inflammatory gene programs. Knocking down LRP1 abolished the benefits, indicating the receptor is required. In vivo, intravitreal injection of AlpNPs attenuated retinal inflammation and preserved RGCs in AOH.
Together, the findings position microglial lipid metabolic dysfunction, and specifically loss of LRP1-PPARγ signaling, as a contributor to glaucomatous neurodegeneration, and LRP1 as a candidate therapeutic target. They also suggest circulating LRP1 might be explored as a biomarker.
Caveats: this is preclinical work. Acute ischemia-reperfusion pressure elevation only partly mimics chronic human glaucoma. Human serum data come from a limited cohort and show association only. Intravitreal nanoparticle delivery, long-term safety, dosing and effects on visual function would need further study before any clinical use. The available text was truncated, so some detail (sample sizes, full in vivo outcomes) could not be verified.
Principales conclusions
- Retinal microglia in the acute ocular hypertension model accumulated lipid droplets, lost LRP1 and shifted toward a pro-inflammatory M1-like phenotype.
- Serum LRP1 was significantly lower in POAG and PACG patients than in age-related cataract controls, suggesting a systemic lipid-metabolic signature.
- Alpinetin PLGA nanoparticles were taken up by microglia, cut lipid accumulation, favored M2 polarization and reduced microglial proliferation and migration.
- AlpNPs bound LRP1 and enhanced its interaction with PPARγ, activating LXRα-ABCA1 cholesterol efflux; LRP1 knockdown abolished the benefit.
- Intravitreal AlpNPs reduced retinal inflammation and preserved retinal ganglion cells in the acute ocular hypertension model.
Méthodologie
Researchers combined an acute ocular hypertension animal model (fundus imaging, H&E, RGC counts, flow cytometry, western blot, immunofluorescence), GEO transcriptomic analysis (limma, |logFC|>0.5, p<0.05), and ELISA of serum from glaucoma patients and cataract controls. They then made alpinetin-loaded PLGA nanoparticles and tested them in microglia, including LRP1 knockdown and binding/pathway experiments, and by intravitreal injection in vivo. Group sizes shown in the figures were small (n=3–5), with one-way ANOVA.
Limites de l'étude
All therapeutic evidence is preclinical and comes from an acute ischemia-reperfusion pressure model, which does not fully reflect chronic human glaucoma. The patient serum comparison is associational and cross-sectional, and its size and confounders are not clear from the available text. Visual function outcomes, long-term nanoparticle safety and intravitreal delivery feasibility were not evident in the provided excerpt, which was truncated.
Ce résumé vous a plu ?
Recevez les dernières recherches sur la longévité dans votre boîte de réception chaque semaine.
Saisissez votre e-mail pour vous abonner :